Remix Therapeutics
PrivateLast Round
Private Placement
Jun 24, 2026
Est. Valuation
$326M
Total Funding Raised
$151M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Remix Therapeutics operates in Healthcare & Life Sciences and is based in Watertown, Massachusetts. Its latest recorded funding round was a VC Round in January 2024.
Remix Therapeutics is a biotechnology company that develops small molecule therapies designed to reprogram RNA processing to treat diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remix Therapeutics Comparables
Compare Remix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 89% | |
| Skyhawk Therapeutics | 86% | |
| Accent Therapeutics | 86% |
For institutional investors. Book with your work email.
Remix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 24, 2026 | ||||
| VC Round | Jan 3, 2024 | ||||
| Series B | May 17, 2022 | ||||
| Series A | Dec 8, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Remix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A, Private Placement, Series B, VC Round, Seed |
| Surveyor Capital | VC Round, Series B |
| The Chernin Group | Series A, Series B, VC Round |
| ARCH Venture Partners | Series A, VC Round, Series B |
| Forge Life Science Partners | Private Placement |
| Foresite Capital | VC Round, Private Placement, Series B, Series A |
| Alexandria Venture Investments | Series A, VC Round, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
$100M round led by Decheng Capital.
- May 17, 2026
Monthly visitors increased 37% MoM, reaching 4.5K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 6, 2026
Remix Therapeutics, Inc. appoints Michael Landsittel to its Board of Directors in Massachusetts on Oct 6th '26.
- hiresSep 9, 2026
Remix Therapeutics, Inc. appoints Nicole Sweeny as Chief Commercial Officer to lead commercial strategy and launch readiness in Massachusetts on Sep 9th '26.
- attends_eventSep 1, 2026
Remix Therapeutics, Inc.'s co-founder and CEO will present a corporate overview at the 21st Annual Wells Fargo Healthcare Conference in Massachusetts on Sep 8th '26.
For institutional investors. Book with your work email.
Remix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Remix Therapeutics's valuation, stock price, and market status.
Is Remix Therapeutics a public or private company?
Remix Therapeutics is a private company.
What is the current stock price of Remix Therapeutics?
Remix Therapeutics is a private company, so its shares have no public market price. Caplight tracks Remix Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Remix Therapeutics worth (valuation)?
Remix Therapeutics's valuation is estimated at $326.0M based on funding round data.
Can I buy Remix Therapeutics stock?
Remix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Remix Therapeutics's last funding round?
Remix Therapeutics's most recent funding round was Private Placement on June 24, 2026.
Who are the main investors in Remix Therapeutics?
Key investors in Remix Therapeutics include The Column Group, The Chernin Group, Foresite Capital, Citadel, Atlas Venture.
Will Remix Therapeutics IPO soon?
No public IPO plans have been announced for Remix Therapeutics.
How can I track Remix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Remix Therapeutics's shares on secondary markets.